|
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
| Capitalization1 |
126 236 | 124 047 | 143 240 | 150 549 | 150 549 | - |
| Entreprise Value (EV)1 |
118 748 | 128 672 | 164 232 | 168 864 | 164 970 | 161 047 |
| P/E ratio |
64,6x | 15,4x | 18,7x | 21,6x | 18,5x | 16,6x |
| Yield |
2,65% | 2,71% | 2,41% | 2,45% | 2,62% | 2,89% |
| Capitalization / Revenue |
5,52x | 5,22x | 6,13x | 5,93x | 5,69x | 5,51x |
| EV / Revenue |
5,20x | 5,42x | 7,03x | 6,66x | 6,24x | 5,90x |
| EV / EBITDA |
8,72x | 9,32x | 12,3x | 11,1x | 10,8x | 10,2x |
| Price to Book |
4,97x | 9,81x | 14,7x | 13,6x | 11,6x | 9,87x |
| Nbr of stocks (in thousands) |
725 911 | 637 219 | 594 184 | 582 169 | 582 169 | - |
| Reference price (USD) |
174 | 195 | 241 | 259 | 259 | 259 |
| Last update |
02/01/2018 | 01/29/2019 | 01/30/2020 | 01/19/2021 | 01/19/2021 | 01/19/2021 |
|
1 USD in Million Estimates
|
|
| Income Statement Evolution | |
|
|
|
| Annual Income Statement Data |
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
| Net sales1 |
22 849 | 23 747 | 23 362 | 25 372 | 26 446 | 27 314 |
| EBITDA1 |
13 613 | 13 803 | 13 363 | 15 156 | 15 318 | 15 782 |
| Operating profit (EBIT)1 |
11 658 | 11 857 | 11 157 | 12 316 | 12 652 | 13 177 |
| Operating Margin |
51,0% | 49,9% | 47,8% | 48,5% | 47,8% | 48,2% |
| Pre-Tax Profit (EBT)1 |
9 597 | 9 545 | 9 138 | 8 788 | 9 506 | 9 944 |
| Net income1 |
1 979 | 8 394 | 7 842 | 7 146 | 8 154 | 8 954 |
| Net margin |
8,66% | 35,3% | 33,6% | 28,2% | 30,8% | 32,8% |
| EPS2 |
2,69 | 12,6 | 12,9 | 12,0 | 14,0 | 15,5 |
| Dividend per Share2 |
4,60 | 5,28 | 5,80 | 6,35 | 6,77 | 7,47 |
| Last update |
02/01/2018 | 01/29/2019 | 01/30/2020 | 01/22/2021 | 01/22/2021 | 01/22/2021 |
|
1 USD in Million 2 USD Estimates
|
|
|
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
| Net Debt1 |
- | 4 625 | 20 992 | 18 316 | 14 421 | 10 498 |
| Net Cash position1 |
7 488 | - | - | - | - | - |
| Leverage (Debt / EBITDA) |
-0,55x | 0,34x | 1,57x | 1,21x | 0,94x | 0,67x |
| Free Cash Flow1 |
9 600 | 10 558 | 8 532 | 10 384 | 10 291 | 10 428 |
| ROE (Net Profit / Equities) |
33,6% | 50,7% | 81,4% | 86,4% | 78,2% | 74,7% |
| Shareholders' equity1 |
5 898 | 16 546 | 9 630 | 8 266 | 10 427 | 11 988 |
| ROA (Net Profit / Asset) |
11,7% | 11,5% | 14,3% | 13,0% | 13,4% | 14,6% |
| Assets1 |
16 864 | 73 182 | 54 778 | 54 896 | 60 693 | 61 531 |
| Book Value Per Share2 |
35,0 | 19,8 | 16,4 | 19,0 | 22,3 | 26,2 |
| Cash Flow per Share2 |
15,2 | 17,0 | 15,0 | 18,0 | 19,3 | 20,2 |
| Capex1 |
700 | 738 | 618 | 615 | 678 | 689 |
| Capex / Sales |
3,06% | 3,11% | 2,65% | 2,43% | 2,56% | 2,52% |
| Last update |
02/01/2018 | 01/29/2019 | 01/30/2020 | 01/26/2021 | 01/26/2021 | 01/26/2021 |
|
1 USD in Million 2 USD Estimates
|
|
|
|
|
|
Financial data source
© 2021 S&P Global Market Intelligence
|
|
|
Analysis: U.S. drugmakers, bracing for price cuts, shift election support toward Democrats |
Capitalization (USD) 150 548 803 063 Net sales (USD) 23 362 000 000 Number of employees 23 400 Sales / Employee (USD) 998 376 Free-Float capitalization (USD) 150 265 583 309 Avg. Exchange 20 sessions (USD) 586 593 681 Average Daily Capital Traded 0,39%
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Evolution Valeur d'Entreprise / EBITDA
|
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
